Dr. Lal Path Labs Ltd. has informed the Exchange about Senior Management Personnel

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

LALPATHLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+13.8%Reaction day

₹1374.00

prior close

₹1390.40

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%+12.8% vs market

Healthcare Service Provider peers, median of 25sector+1.9%+12.0% vs sector

On the reaction day the stock moved 12.8 pts more than Nifty Smallcap 250 and 12.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+3.8

15m

+2.9

30m

+5.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+13.8+1.0+12.8+1.9+12.0

Next day

+11.6+1.2+10.5+0.3+11.3

+15.1+3.0+12.1+2.0+13.1

+12.5+4.1+8.5+2.7+9.8

+20.5+4.2+16.2+3.4+17.1

+19.9+3.1+16.8+4.5+15.4

+15.6+0.3+15.3+2.0+13.6

15d

+16.8+1.5+15.3+3.3+13.5

+13.0+1.9+11.1-0.2+13.2

+23.1+8.1+15.0+1.3+21.8

+37.4+8.7+28.6+2.7+34.6

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Lal Path Labs reported FY2026 revenue of Rs 27,629 million, up 12.2% from Rs 24,614 million in FY2025. Net profit grew to Rs 5,098 million from Rs 4,922 million, a 3.6% increase. The Board recommended a final dividend of Rs 4 per share (total annual dividend Rs 20.5 per share including Rs 16.5 interim dividends). Key expansions include acquisition of 100% stake in Shahbazkers Diagnostic Centre and incorporation of a new wholly-owned subsidiary in Dubai. Two senior management personnel (Dr. Reena Nakra and Dr. Saloni Khera) were designated as SMPs. Auditors gave clean (unmodified) opinions on both standalone and consolidated results. The 32nd AGM is scheduled for July 25, 2026.

Likely market impact

Strong financial performance with consistent revenue growth and shareholder-friendly dividend policy. The Dubai subsidiary and acquisition of SDCPL signal continued geographic and operational expansion, which could support long-term growth prospects for investors.